Ikonisys said that oncoFISH her2 is a fully automated microscopy application for the determination of HER2 status in human breast cancer specimens processed with Abbott’s PathVysion HER2 DNA probe kit.
The test runs on the company’s CellOptics platform, featuring the Ikoniscope, a proprietary high-throughput, digital microscope, and provides ‘walk-away’ automated testing of the HER2 gene to provide an early and accurate indication for gene amplification, according to Ikonisys.
Petros Tsipouras, chairman and CEO of Ikonisys, said: “With this test, laboratories and hospitals will have an economical and accurate method for automating their FISH testing of HER2 breast cancer. This will help them to standardize their diagnostic testing procedures, decrease the wait time for test results and, more importantly, help labs to compensate for the nationwide shortage of lab technicians by enabling them to best maximize their time.”